FPA
ASBPW

First Pacific Advisors’s Aspire Biopharma Warrant ASBPW Stock Holding History

First Pacific Advisors’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,482
Closed -$783 – 75
2024
Q2 		$783 Hold
28,482
– – ﹤0.01% 72
2024
Q1 		$857 Buy
+28,482
New +$1.11K ﹤0.01% 74

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

First Pacific Advisors's ASBPW Position: Q3 2024 in Review

First Pacific Advisors sold out of Aspire Biopharma Warrant (ASBPW) in Q3 2024, closing a stake of 28,482 shares — an estimated $783 sold.

First Pacific Advisors first reported a position in ASBPW in Q1 2024 and held it in 2 quarters. The position peaked at $857 in Q1 2024. 30 funds tracked by Wall St. Rank hold ASBPW as of Q3 2024.

  • First Pacific Advisors reported no remaining Aspire Biopharma Warrant position as of Q3 2024 after selling out during the quarter.
  • First Pacific Advisors sold 28,482 Aspire Biopharma Warrant shares in Q3 2024, an estimated $783.
  • First Pacific Advisors first reported a position in Aspire Biopharma Warrant in Q1 2024 and held it in 2 quarters.
  • First Pacific Advisors's Aspire Biopharma Warrant position peaked at $857 in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q3 2024.

Based on First Pacific Advisors's 13F filing for Q3 2024, filed 4 Nov 2024.